HC Wainwright Analysts Decrease Earnings Estimates for ACAD

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Equities research analysts at HC Wainwright reduced their Q3 2026 earnings per share (EPS) estimates for shares of ACADIA Pharmaceuticals in a report issued on Thursday, May 7th. HC Wainwright analyst A. Ghosh now forecasts that the biopharmaceutical company will post earnings per share of $0.13 for the quarter, down from their prior forecast of $0.16. HC Wainwright currently has a “Buy” rating and a $37.00 target price on the stock. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.45 per share. HC Wainwright also issued estimates for ACADIA Pharmaceuticals’ Q4 2026 earnings at $0.21 EPS, FY2026 earnings at $0.37 EPS, FY2027 earnings at $1.70 EPS, FY2028 earnings at $2.76 EPS, FY2029 earnings at $3.09 EPS and FY2030 earnings at $3.22 EPS.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.02). The firm had revenue of $268.10 million during the quarter, compared to analysts’ expectations of $280.25 million. ACADIA Pharmaceuticals had a return on equity of 10.23% and a net margin of 34.30%.ACADIA Pharmaceuticals’s revenue for the quarter was up 9.7% on a year-over-year basis. During the same period in the previous year, the company earned $0.11 earnings per share.

Several other research analysts have also issued reports on ACAD. Stifel Nicolaus decreased their price target on shares of ACADIA Pharmaceuticals from $25.00 to $24.00 and set a “hold” rating for the company in a research note on Thursday, February 26th. Wall Street Zen lowered shares of ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, January 31st. TD Cowen raised their target price on shares of ACADIA Pharmaceuticals from $35.00 to $37.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. JPMorgan Chase & Co. lifted their target price on shares of ACADIA Pharmaceuticals from $31.00 to $34.00 and gave the company an “overweight” rating in a report on Wednesday, March 4th. Finally, Weiss Ratings cut ACADIA Pharmaceuticals from a “hold (c+)” rating to a “hold (c)” rating in a research report on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, ACADIA Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $31.21.

ACADIA Pharmaceuticals Trading Up 5.1%

Shares of ACAD stock opened at $22.58 on Friday. ACADIA Pharmaceuticals has a 12 month low of $14.68 and a 12 month high of $28.35. The stock has a market cap of $3.87 billion, a PE ratio of 10.26, a price-to-earnings-growth ratio of 22.40 and a beta of 0.86. The company’s fifty day moving average price is $22.06 and its 200-day moving average price is $23.90.

Insider Activity at ACADIA Pharmaceuticals

In related news, insider James Kihara sold 1,332 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $21.79, for a total value of $29,024.28. Following the completion of the transaction, the insider directly owned 29,129 shares in the company, valued at $634,720.91. The trade was a 4.37% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Jennifer J. Rhodes sold 6,950 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $23.38, for a total value of $162,491.00. Following the completion of the transaction, the executive vice president directly owned 7,609 shares in the company, valued at $177,898.42. This trade represents a 47.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 15,527 shares of company stock valued at $350,917 over the last 90 days. Corporate insiders own 26.20% of the company’s stock.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

Institutional investors have recently modified their holdings of the business. Farther Finance Advisors LLC increased its holdings in ACADIA Pharmaceuticals by 67.5% in the 4th quarter. Farther Finance Advisors LLC now owns 958 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 386 shares in the last quarter. Meeder Asset Management Inc. bought a new position in ACADIA Pharmaceuticals during the 4th quarter valued at about $26,000. Geneos Wealth Management Inc. boosted its holdings in shares of ACADIA Pharmaceuticals by 113.0% during the 3rd quarter. Geneos Wealth Management Inc. now owns 1,425 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 756 shares during the last quarter. Smartleaf Asset Management LLC grew its stake in shares of ACADIA Pharmaceuticals by 107.0% in the third quarter. Smartleaf Asset Management LLC now owns 1,712 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 885 shares during the period. Finally, Transamerica Financial Advisors LLC boosted its holdings in ACADIA Pharmaceuticals by 304.5% in the fourth quarter. Transamerica Financial Advisors LLC now owns 1,335 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 1,005 shares during the last quarter. 96.71% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting ACADIA Pharmaceuticals

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: Company reaffirmed 2026 financial guidance and reported 1Q26 revenue growth (total revenues $268.1M) with DAYBUE STIX generating ~$101M, which management highlighted as a strong commercial start and a key driver of upside potential. Acadia Reports Q1 Results & Reaffirms Guidance
• Positive Sentiment: Management tone on the Q1 earnings call was constructive — the company signaled confidence in the commercial rollout and pipeline progress, which can support investor sentiment despite near-term execution noise. ACADIA Signals Confident Path After Q1 Call
• Neutral Sentiment: Revenue was up ~9.7% year-over-year, and margins remain healthy (net margin ~34%). These fundamentals are supportive but may be priced in given prior guidance. MarketBeat Q1 Summary & Conference Call
• Negative Sentiment: Quarterly EPS ($0.02) and revenue ($268.1M) missed street estimates (consensus EPS ~$0.04; revenue ~$280.3M), raising concerns about near-term profitability and execution versus expectations. ACAD Q1 Earnings & Revenues Miss Estimates
• Negative Sentiment: HC Wainwright trimmed EPS forecasts across near- and long-term horizons (notably FY2026 EPS cut from $0.46 to $0.37 and Q3/Q4 2026 cuts) — the firm still carries a Buy rating and $37 target, but the estimate downgrades signal reduced near-term expectations that could weigh on sentiment. (HC Wainwright research note, May 7)
• Neutral Sentiment: Full earnings materials and call transcript are available for deeper diligence if you want to parse commercial uptake metrics and R&D updates before taking a position. Earnings Call Transcript

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.